Rhabdomyosarcoma (RMS) is a soft tissue sarcoma and is most frequently found in children. In RMS, there are two major subtypes, that is, embryonal RMS and alveolar RMS (ARMS). ARMS has exclusively the worse prognosis and is caused by formation of the chimeric PAX3-FOXO1 gene. Regarding cancer, the Warburg effect is known as a feature of cancer-specific metabolism. Polypyrimidine tract-binding protein 1 (PTBP1), a splicer of pyruvate kinase muscle (PKM) mRNA, is a positive regulator of cancer-specific energy metabolism. We investigated the expression and effects of muscle-specific miR-1 and miR-133b on RMS cells (RD, KYM-1, Rh30, and Rh41) from the view of energy metabolism and regulation of the chimeric gene. As a result, downregulated miR-1 and miR-133b/upregulated PTBP1 were found in RMS cell lines as well as in RMS clinical cases. Ectopic expression of either miR in both types of RMS cells induced autophagic cell death through silencing of PTBP1. Interestingly, we validated that miR-133b also knock downed PAX3-FOXO1. Moreover, we found that PAX3-FOXO1 positively regulated the PKM2-dominant expression through enhanced expression of PTBP1. These findings suggest that the miR-1 and miR-133b/PTBP1 axis and miR-133b/PAX3-FOXO1/PTBP1 axis contributed to the maintenance of cancer-specific energy metabolism.
Get full access to this article
View all access options for this article.
References
1.
GaliliN, DavisRJ, FredericksWJ, MukhopadhyayS, RauscherFJ3rd, EmanuelBS, RoveraG and BarrFG. (1993). Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet, 5:230–235.
2.
MissiagliaE, WilliamsonD, ChisholmJ, WirapatiP, PierronG, PetelF, ConcordetJP, ThwayK, OberlinO, et al. (2012). PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol, 30:1670–1677.
3.
FredericksWJ, GaliliN, MukhopadhyayS, RoveraG, BennicelliJ, BarrFG and RauscherFJ3rd. (1995). The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol, 15:1522–1535.
4.
AndersonMJ, SheltonGD, CaveneeWK and ArdenKC. (2001). Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci U S A, 98:1589–1594.
5.
MezaJL, AndersonJ, PappoAS, MeyerWH and Children's OncologyG. (2006). Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol, 24:3844–3851.
6.
MarshallAD and GrosveldGC. (2012). Alveolar rhabdomyosarcoma—the molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. Skelet Muscle, 2:25.
7.
HosoiH. (2016). Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan. Pediatr Int, 58:81–87.
8.
WarburgO. (1956). On the origin of cancer cells. Science, 123:309–314.
9.
NoguchiT, InoueH and TanakaT. (1986). The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem, 261:13807–13812.
10.
ClowerCV, ChatterjeeD, WangZ, CantleyLC, Vander HeidenMG and KrainerAR. (2010). The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A, 107:1894–1899.
11.
ChenM, ZhangJ and ManleyJL. (2010). Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res, 70:8977–8980.
LeeRC, FeinbaumRL and AmbrosV. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75:843–854.
14.
AmbrosV. (2003). MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell, 113:673–676.
15.
AkaoY, NakagawaY and NaoeT. (2006). let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull, 29:903–906.
16.
AkaoY, NakagawaY and NaoeT. (2006). MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep, 16:845–850.
17.
CroceCM. (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet, 10:704–714.
18.
TaniguchiK, SugitoN, KumazakiM, ShinoharaH, YamadaN, NakagawaY, ItoY, OtsukiY, UnoB, et al. (2015). MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett, 363:17–27.
19.
LiuN, WilliamsAH, KimY, McAnallyJ, BezprozvannayaS, SutherlandLB, RichardsonJA, Bassel-DubyR and OlsonEN. (2007). An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci U S A, 104:20844–20849.
20.
XuC, LuY, PanZ, ChuW, LuoX, LinH, XiaoJ, ShanH, WangZ and YangB. (2007). The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci, 120:3045–3052.
21.
RaoPK, KumarRM, FarkhondehM, BaskervilleS and LodishHF. (2006). Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl Acad Sci U S A, 103:8721–8726.
22.
TaulliR, BersaniF, FoglizzoV, LinariA, VignaE, LadanyiM, TuschlT and PonzettoC. (2009). The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest, 119:2366–2378.
MacquarrieKL, YaoZ, YoungJM, CaoY and TapscottSJ. (2012). miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells. Skelet Muscle, 2:7.
25.
HannaJA, GarciaMR, GoJC, FinkelsteinD, KodaliK, PagalaV, WangX, PengJ and HatleyME. (2016). PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma. Cell Death Dis, 7:e2256.
26.
MiyachiM, TsuchiyaK, YoshidaH, YagyuS, KikuchiK, MisawaA, IeharaT and HosoiH. (2010). Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun, 400:89–93.
27.
KikuchiK, TsuchiyaK, OtabeO, GotohT, TamuraS, KatsumiY, YagyuS, Tsubai-ShimizuS, MiyachiM, et al. (2008). Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun, 365:568–574.
28.
AkaoY, NakagawaY, HirataI, IioA, ItohT, KojimaK, NakashimaR, KitadeY and NaoeT. (2010). Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther, 17:398–408.
29.
TangY, SimoneauAR, LiaoWX, YiG, HopeC, LiuF, LiS, XieJ, HolcombeRF, et al. (2009). WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther, 8:458–468.
30.
NoguchiS, IwasakiJ, KumazakiM, MoriT, MaruoK, SakaiH, YamadaN, ShimadaK, NaoeT, KitadeY, et al. (2013). Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo. Mol Ther, 21:1204–1211.
31.
KabeyaY, MizushimaN, UenoT, YamamotoA, KirisakoT, NodaT, KominamiE, OhsumiY and YoshimoriT. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J, 19:5720–5728.
32.
KumaA, MatsuiM and MizushimaN. (2007). LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy: caution in the interpretation of LC3 localization. Autophagy, 3:323–328.
33.
ShimizuS, KanasekiT, MizushimaN, MizutaT, Arakawa-KobayashiS, ThompsonCB and TsujimotoY. (2004). Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol, 6:1221–1228.
34.
SelbachM, SchwanhausserB, ThierfelderN, FangZ, KhaninR and RajewskyN. (2008). Widespread changes in protein synthesis induced by microRNAs. Nature, 455:58–63.
35.
ChristofkHR, Vander HeidenMG, HarrisMH, RamanathanA, GersztenRE, WeiR, FlemingMD, SchreiberSL and CantleyLC. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 452:230–233.
36.
TaniguchiK, SakaiM, SugitoN, KumazakiM, ShinoharaH, YamadaN, NakayamaT, UedaH, NakagawaY, et al. (2016). PTBP1-associated microRNA-1 and −133b suppress the Warburg effect in colorectal tumors. Oncotarget, 7:18940–18952.
37.
DavidCJ, ChenM, AssanahM, CanollP and ManleyJL. (2010). HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature, 463:364–368.
38.
ShiioY, DonohoeS, YiEC, GoodlettDR, AebersoldR and EisenmanRN. (2002). Quantitative proteomic analysis of Myc oncoprotein function. EMBO J, 21:5088–5096.
39.
SchlosserI, HolzelM, HoffmannR, BurtscherH, KohlhuberF, SchuhmacherM, ChapmanR, WeidleUH and EickD. (2005). Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line. Oncogene, 24:520–524.
40.
ChenX, XuH, YuanP, FangF, HussM, VegaVB, WongE, OrlovYL, ZhangW, et al. (2008). Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell, 133:1106–1117.
41.
RaoPK, MissiagliaE, ShieldsL, HydeG, YuanB, ShepherdCJ, ShipleyJ and LodishHF. (2010). Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J, 24:3427–3437.
42.
ChenJF, MandelEM, ThomsonJM, WuQ, CallisTE, HammondSM, ConlonFL and WangDZ. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet, 38:228–233.
43.
WaltersZS, Villarejo-BalcellsB, OlmosD, BuistTW, MissiagliaE, AllenR, Al-LazikaniB, GarrettMD, BlaggJ and ShipleyJ. (2014). JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene, 33:1148–1157.
44.
SogaT, OhashiY, UenoY, NaraokaH, TomitaM and NishiokaT. (2003). Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res, 2:488–494.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
